SG11201400521PA - ANTIBODIES TO CD1d - Google Patents

ANTIBODIES TO CD1d

Info

Publication number
SG11201400521PA
SG11201400521PA SG11201400521PA SG11201400521PA SG11201400521PA SG 11201400521P A SG11201400521P A SG 11201400521PA SG 11201400521P A SG11201400521P A SG 11201400521PA SG 11201400521P A SG11201400521P A SG 11201400521PA SG 11201400521P A SG11201400521P A SG 11201400521PA
Authority
SG
Singapore
Prior art keywords
cd1d
antibodies
Prior art date
Application number
SG11201400521PA
Other languages
English (en)
Inventor
Jonathan Kannan Nambiar
Lynn Dorothy Poulton
Adam Clarke
Andrew James Pow
Debra Tamvakis
George Kopsidas
Anthony Gerard Doyle
Matthew Pollard
Huseyin Mustafa
Original Assignee
Teva Pharmaceuticals Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904190A external-priority patent/AU2011904190A0/en
Application filed by Teva Pharmaceuticals Australia Pty Ltd filed Critical Teva Pharmaceuticals Australia Pty Ltd
Publication of SG11201400521PA publication Critical patent/SG11201400521PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201400521PA 2011-10-14 2012-10-15 ANTIBODIES TO CD1d SG11201400521PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161547307P 2011-10-14 2011-10-14
AU2011904190A AU2011904190A0 (en) 2011-10-14 Antibodies to CD1d
PCT/AU2012/001247 WO2013053021A1 (en) 2011-10-14 2012-10-15 ANTIBODIES TO CD1d

Publications (1)

Publication Number Publication Date
SG11201400521PA true SG11201400521PA (en) 2014-08-28

Family

ID=48081279

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201400521PA SG11201400521PA (en) 2011-10-14 2012-10-15 ANTIBODIES TO CD1d

Country Status (14)

Country Link
US (1) US20140286957A1 (enExample)
EP (1) EP2766042A4 (enExample)
JP (1) JP2015502915A (enExample)
KR (1) KR20140108520A (enExample)
CN (1) CN104144700B (enExample)
AU (1) AU2012323781B8 (enExample)
BR (1) BR112014008691A2 (enExample)
CA (1) CA2850961A1 (enExample)
EA (1) EA201400447A1 (enExample)
IL (1) IL231975A0 (enExample)
MX (1) MX2014004326A (enExample)
SG (1) SG11201400521PA (enExample)
WO (1) WO2013053021A1 (enExample)
ZA (1) ZA201401776B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6743051B2 (ja) * 2015-01-27 2020-08-19 ラヴァ・セラピューティクス・ベー・フェー Ｃｄ１ｄを標的とする単一ドメイン抗体
HUE056433T2 (hu) * 2016-04-08 2022-02-28 Adaptimmune Ltd T-sejt receptorok
US11505590B2 (en) * 2016-04-08 2022-11-22 Immunocore Limited T cell receptors
ES2788188T5 (es) * 2016-04-08 2023-10-24 Adaptimmune Ltd Receptores de linfocitos T
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
CN110621321B (zh) * 2017-03-15 2024-06-21 浩康生物系统公司 用于造血干细胞移植的组合物和方法
WO2020060405A1 (en) * 2018-09-19 2020-03-26 Lava Therapeutics B.V. Dual acting cd1d immunoglobulin
GB201820006D0 (en) 2018-12-07 2019-01-23 Lifearc Humanised anti-IL17BR antibody
PE20231187A1 (es) * 2020-08-18 2023-08-15 Cephalon Llc Anticuerpos anti-par-2 y metodos de uso de los mismos
US20240050569A1 (en) * 2020-12-18 2024-02-15 Bioardis, Llc Mesothelin binding molecules and uses thereof
IL319060A (en) 2022-08-18 2025-04-01 Immunocore Ltd MAGE A4-specific T-cell receptor fusion proteins
CN116217704B (zh) * 2022-10-25 2025-08-15 南京医科大学 一种抑制肝细胞凋亡的表面分子及其应用
KR20250128342A (ko) * 2022-12-21 2025-08-27 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 입양 면역요법을 위한 향상된 기능을 갖는 cd3 및 itcr을 발현하는 조작된 자연살해세포
WO2024226794A1 (en) * 2023-04-26 2024-10-31 The Trustees Of Indiana University Composition and methods for treatment of spinal cord injury and traumatic brain injury

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE339452T1 (de) * 1998-07-09 2006-10-15 Brian J Nickoloff Methode zur behandlung von krankheiten durch veränderung der wechselwirkung zwischen natural killer rezeptoren auf t-zellen mit ihren jeweiligen liganden
WO2003092615A2 (en) * 2002-05-01 2003-11-13 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
WO2008100912A1 (en) * 2007-02-12 2008-08-21 The General Hospital Corporation Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
US8012484B2 (en) * 2007-04-12 2011-09-06 University Of Virginia Patent Foundation Method of treating ischemia reperfusion injury by inhibiting NKT cell activity

Also Published As

Publication number Publication date
BR112014008691A2 (pt) 2017-06-13
EA201400447A1 (ru) 2014-09-30
WO2013053021A1 (en) 2013-04-18
CA2850961A1 (en) 2013-04-18
JP2015502915A (ja) 2015-01-29
EP2766042A1 (en) 2014-08-20
US20140286957A1 (en) 2014-09-25
NZ622050A (en) 2016-07-29
AU2012323781A8 (en) 2015-05-14
AU2012323781B2 (en) 2015-04-23
CN104144700B (zh) 2016-10-19
EP2766042A4 (en) 2015-05-27
ZA201401776B (en) 2016-01-27
MX2014004326A (es) 2014-09-25
IL231975A0 (en) 2014-05-28
AU2012323781B8 (en) 2015-05-14
AU2012323781A1 (en) 2014-03-27
CN104144700A (zh) 2014-11-12
KR20140108520A (ko) 2014-09-11

Similar Documents

Publication Publication Date Title
IL272035A (en) Anti IL–36R antibodies
IL259826A (en) Anti-alphabetatisiar antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
ZA201307983B (en) Anti-b7-h3 antibody
IL228001B (en) Antibodies to 70cd
IL231975A0 (en) Antibodies to cd1d
IL229254A0 (en) Therapeutic antibodies
IL230719A0 (en) highly galactosylated antibodies
IL232017A0 (en) Antibodies of human origin to inkt
EP2764325A4 (en) USE OF A VIDEOGRAMMETRY FOR THE MANUFACTURE OF PARTS
TWI563004B (en) Anti-hxcr1 antibody
GB201121564D0 (en) Use of antibody
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
PT2719842E (pt) Reforço para utilização estrutural
AU2011904190A0 (en) Antibodies to CD1d
GB201116456D0 (en) Improvements relating to foorwear
GB201100188D0 (en) Structural members
ZA201308992B (en) Therapeutic antibodies